While radiopharmaceuticals can be difficult to manufacture, they are an attractive way to more selectively direct radiation to tumor cells while sparing healthy tissue.
Prostate cancer in particular has been a target of choice for radiopharmaceutical developers looking to add new drugs to surgery, chemotherapy and hormonal treatment options. Novartis, for instance, sells a radiopharmaceutical called Pluvicto for advanced forms of prostate cancer. (It also sells another radiopharmaceutical, Lutathera, for tumors of the pancreas or gastrointestinal tract.)
